Skip to main content

3 Result(s)

within Julius Wehrle Remove this filter Oncology Remove this filter

and

  1. Article

    Open Access

    Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia

    TP53 aberrations reportedly predict favorable responses to decitabine (DAC) in acute myeloid leukemia (AML). We evaluated clinical features and outcomes associated with chromosome 17p loss or TP53 gene mutations ...

    Heiko Becker, Dietmar Pfeifer, Gabriele Ihorst, Milena Pantic… in Annals of Hematology (2020)

    Download PDF (1093 KB) View Article

  2. No Access

    Chapter

    Ponatinib: A Third-Generation Inhibitor for the Treatment of CML

    The establishment of imatinib as the standard therapy for CML marked the beginning of a new era of treatment. Due to occurring intolerance and resistance against the drug, the development of new inhibitors was...

    Julius Wehrle, Nikolas von Bubnoff in Small Molecules in Hematology (2018)

  3. No Access

    Chapter

    Ponatinib: A Third-Generation Inhibitor for the Treatment of CML

    The establishment of imatinib as the standard therapy for CML marked the beginning of a new era of treatment. Due to occurring intolerance and resistance against the drug, develo** newer inhibitors was promo...

    Julius Wehrle, Heike L. Pahl, Nikolas von Bubnoff in Small Molecules in Oncology (2014)